Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Istituto Superiore Di Sanita

First - Societa' a Responsabilita' Limitata Con Socio Unico

Anna Teresa Palamara

Enrico Garaci

Antonello Mai

Mauro Magnani

Andrea Savarino

Luigia Rossi

Marina Lusic

Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a 'chain reaction' is sparked. This 'chain reaction' induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.

Treatment of retroviral reservoirs exploiting oxidative stress

The use of resveratrol is described fir the preparation of a medicament for the treatment of influenza. Said medicament exerts itself in therapeutic activity through inhibition of viral replication.

Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections

Growing community of inventors

Rome, Italy

Anna Teresa Palamara